Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922893 | 0.92 | CCR5 (0.45) | LMNASMN1; SMN2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL4924450 | 0.92 | ACKR3 (0.48) | ACKR3CHRM3UBE2MDCUN1D1 | |
| SCHEMBL4916411 | 0.91 | CHRM3 (0.42) | LMNASMN1; SMN2CHRM3MEN1KMT2A | |
| SCHEMBL4924357 | 0.91 | ALDH1A1 (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL4923464 | 0.90 | POLB (0.48) | ACKR3LMNAUBE2MDCUN1D1ROCK2 | |
| SCHEMBL4914291 | 0.89 | UBE2M (0.45) | LMNASMN1; SMN2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL4924883 | 0.89 | TSHR (0.49) | ACKR3SMN1; SMN2CHRM3 | |
| SCHEMBL4923492 | 0.88 | PPARG (0.46) | LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4924440 | 0.88 | ALDH1A1 (0.49) | ACKR3 | |
| SCHEMBL4911904 | 0.88 | L3MBTL1 (0.49) | ACKR3LMNASMN1; SMN2UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | ACKR3 5/4885LMNA 2533/4885SMN1; SMN2 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.